Use of gadolinium-based contrast agents in multiple sclerosis: a review by the ESMRMB-GREC and ESNR Multiple Sclerosis Working Group

被引：0

作者：

Àlex Rovira

Fabio M. Doniselli

Cristina Auger

Lukas Haider

Jerome Hodel

Mariasavina Severino

Mike P. Wattjes

Aart J. van der Molen

Bas Jasperse

Carlo A. Mallio

Tarek Yousry

Carlo C. Quattrocchi

机构：

[1] University Hospital Vall d’Hebron,Section of Neuroradiology, Department of Radiology

[2] Autonomous University of Barcelona,Department of Biomedical Imaging and Image Guided Therapy

[3] Neuroradiology Unit,Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology

[4] Fondazione IRCCS Istituto Neurologico Carlo Besta,Department of Radiology

[5] Medical University of Vienna,Neuroradiology Unit

[6] University College London,Department of Diagnostic and Interventional Neuroradiology

[7] Groupe Hospitalier Paris-Saint Joseph,Department of Radiology

[8] IRCCS Istituto Giannina Gaslini,Department of Radiology and Nuclear Medicine, MS Center Amsterdam

[9] Hannover Medical School,Research Unit of Radiology, Department of Medicine and Surgery

[10] Leiden University Medical Center,Lysholm Department of Neuroradiology, UCLH National Hospital for Neurology and Neurosurgery, Neuroradiological Academic Unit

[11] Amsterdam University Medical Center,Centre for Medical Sciences CISMed

[12] Fondazione Policlinico Universitario Campus Bio-Medico,Radiology, Multizonal Unit of Rovereto and Arco

[13] Università Campus Bio-Medico Di Roma,undefined

[14] UCL Institute of Neurology,undefined

[15] University of Trento,undefined

[16] APSS Provincia Autonoma Di Trento,undefined

来源：

European Radiology | 2024年 / 34卷

关键词：

Gadolinium; Magnetic resonance imaging; Multiple sclerosis; Practice guideline; Safety;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1726 / 1735

页数：9

共 248 条

[1]

Wattjes MP(2021)2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis Lancet Neurol 20 653-670

[2]

Ciccarelli O(2013)Magnetic resonance monitoring of lesion evolution in multiple sclerosis Ther Adv Neurol Disord 6 298-310

[3]

Reich DS(2017)Gadolinium deposition in the brain: summary of evidence and recommendations Lancet Neurol 16 564-570

[4]

Rovira A(2021)A roadmap towards pollution prevention and sustainable development of Gadolinium J Neuroradiol 48 409-411

[5]

Auger C(2023)Skin thickening of the scalp and high signal intensity of dentate nucleus in multiple sclerosis: association with linear versus macrocyclic gadolinium-based contrast agent administration Invest Radiol 58 223-230

[6]

Alonso J(2020)Exposure to gadolinium and neurotoxicity: current status of preclinical and clinical studies Neuroradiology 62 925-934

[7]

Gulani V(2019)Standardized assessment of the signal intensity increase on unenhanced T1-weighted images in the brain: the European Gadolinium Retention Evaluation Consortium (GREC) Task Force position statement Eur Radiol 29 3959-3967

[8]

Calamante F(2017)Gadolinium retention in the body and brain: is it time for an international joint research effort? Radiology 282 12-16

[9]

Shellock FG(2014)High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material Radiology 270 834-841

[10]

Ognard J(2018)Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria Lancet Neurol 17 162-173

← 1 2 3 4 5 6 7 8 9 10 →